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Introduction
MicroRNAs (miRNAs) are quickly gaining recognition for 
their role in many biological processes and disease states 
[1, 2]. MiRNAs are endogenous non-coding single-stranded 
RNAs of approximately 22 nucleotides that regulate gene 
expression by post-transcriptional mechanisms upon 
sequence-specific binding to the 3′ untranslated regions 
(3′ UTRs) [1, 3] or, occasionally, the 5′UTRs [4, 5] or cod-
ing regions [6–8] of their mRNA targets. MiRNAs exhibit 
imperfect complementarity with mRNAs, allowing them 
to regulate multiple genes and thus complicating efforts 
to predict and functionally validate their targets [9]. Since 
their discovery [10], miRNAs have been acknowledged as 
important modulators of gene expression, and deficiency in 
their synthesis or function contributes to many human dis-
eases [11, 12]. MiRNA expression profiles characteristic of 
a particular disorder may serve as a useful diagnostic tool, 
but more importantly, it is the first step towards unraveling 
miRNA functions. Follow-up studies in experimental mod-
els are carried out to identify the protein targets of differen-
tially expressed miRNAs and delineate the signaling path-
ways activated in a diseased state.
Although a wealth of information has been gathered on 
miRNA expression in bladder cancer (BCa), which in this 
respect remains the best-studied disorder, only a few stud-
ies have been carried out in bladder dysfunction. The first 
miRNA profiling in bladder pain syndrome/interstitial cysti-
tis (BPS), which was performed in our laboratory, has identi-
fied several miRNAs, regulating the expression of signaling 
and adhesion molecules [13, 14]. Pain and inflammation are 
characteristic of BPS, which has been suggested to share the 
pathogenetic mechanisms with other inflammatory diseases 
such as asthma, inflammatory bowel disease, and autoim-
mune diseases [15]. These are common co-morbidities 
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of BPS/IC, and miRNA expression and function in these 
immune-mediated diseases has been addressed in a num-
ber of studies. This review projects the miRNA profiling 
and functional data originating from the research in bladder 
cancer and immune-mediated diseases on the BPS-specific 
miRNAs aiming to gain new insight into the pathogenesis of 
this enigmatic disorder, and highlighting the common regu-
latory mechanisms of pain and inflammation.
MicroRNAs—general information
The first miRNAs lin-4 and let-7 were discovered as impor-
tant regulators of the normal temporal control of diverse 
postembryonic developmental events in C. elegans [10, 16]. 
Most miRNA reduce protein synthesis, whereas some, such 
as miR369-3 and miR-373, enhance translation [17, 18]. 
The first link between miRNAs and cancer was made after 
uncovering the deletion of miR-15 and miR-16 in leukemias 
[19], and the potential for the miRNA profiling in cancer 
diagnosis became apparent [20]. This was followed by stud-
ies of the role of miRNAs in cardiovascular [21], neuro-
degenerative [22–24], and autoimmune disease [25, 26]. 
Therapeutic use of miRNAs was pioneered by administra-
tion of miRNAs [27], or their antagonists called antagomirs 
[28], to the affected cells restoring the normal levels of their 
protein targets. The locked nucleic acid (LNA)-antagomirs 
have been successfully introduced into the clinical practice: 
LNA-anti-miR-122 suppresses hepatitis C virus (HCV) rep-
lication in chronically infected animals [29].
The details of miRNA synthesis are well characterized 
and extensively reviewed [30–32]. Most canonical mam-
malian miRNA genes have been identified in introns of the 
protein-coding or noncoding RNAs and around one-third 
of them are located in the introns of target genes [33]. The 
miRNA gene transcripts are the primary precursor RNAs 
(pri-miRNA), which mature in two steps (Fig. 1). Pri-
miRNAs are processed in the nucleus by Drosha–DGCR8 
complex into a ~70-nucleotide RNA molecules [34]. These 
precursor hairpin miRNAs (pre-miRNAs) are then exported 
to the cytoplasm by Exportin-5 (Exp5) [35] and cleaved 
by Dicer-TRBP complex into a ~20-bp miRNA/miRNA* 
duplex. The guide strand of the miRNA/miRNA* duplex 
is usually incorporated into miRNA-induced silencing 
complex (miRISC) and the passenger strand or (miRNA*) 
is released and degraded [36]. The final product is RISC-
loaded mature miRNA, which is guided to its target mRNA 
by means of base pairing (Fig. 1).
Some microRNA, such as miR-877 and miR-1226, 
derive from short intronic hairpins named “mirtrons” [37, 
38]. Mirtrons are spliced from the host gene by the spli-
ceosome, become linearized by debranching enzyme and 
then fold into hairpins, which enter the miRNA-processing 
pathway without Drosha-mediated cleavage [37, 39]. 
Recently, a third pathway of microRNA biogenesis has been 
described: some microRNAs (miR-1225 and miR-1228) do 
not need DGCR8, Dicer, Exportin-5, or Argonaute 2 for 
their biogenesis, which nevertheless involves Drosha. This 
class of microRNAs has been named “simtrons” [40]. The 
miRNA registry in humans includes 18,226 entries for hair-
pin precursor miRNAs, expressing 21,643 mature miRNA 
products [41, 42].
Role of miRNAs in urinary bladder function  
and pathology
Pathogenesis of bladder pain syndrome (BPS)
Bladder pain syndrome (BPS) is a clinical syndrome of pel-
vic pain and urinary urgency-frequency in the absence of a 
specific cause. According to the European Society for the 
Study of Interstitial Cystitis (ESSIC) proposal and Euro-
pean Association of Urology (EAU) guidelines [43], BPS 
is diagnosed on the basis of symptoms of pain associated 
with the urinary bladder, accompanied by at least one other 
symptom, such as day-time and/or night-time urinary fre-
quency after exclusion of confounding symptoms. Overall, 
this disease, which has a significant impact on social and 
psychological well-being, affects approximately 1 million 
patients in the USA alone [44], with at least 230 confirmed 
cases per 100,000 females [45]. The etiology of BPS is 
unknown, and its treatment largely empiric. A multitude 
of pathogenetic mechanisms have been postulated ranging 
from neuroinflammatory to autoimmune or possibly infec-
tious or toxic agents, but an inflammatory component is 
commonly thought to be involved. Epithelial damage has 
often been invoked: the mucinous layer of the healthy blad-
der is often compromised in patients with BPS/IC, as well 
as in some animal models [46, 47].
The integrity of the urothelium is indispensable for the 
healthy bladder [48]. Mechanical or chemical damage, as 
well as a bacterial infection can lead to a compromised 
urothelium allowing urinary solutes to penetrate into the 
interstitium [49]. The loss of epithelial integrity is a pre-
dominant histopathologic finding in biopsies from BPS 
patients [50]. In human BPS patients, the molecular mark-
ers for bladder permeability and proteoglycan core proteins 
are often down-regulated [51, 52]. Recently, we have shown 
that the mRNA levels of the tight junction (TJ) proteins 
ZO-1, JAM-1, occludin, and tight claudins, normally pre-
sent in water impermeable epithelia and abundant in normal 
urothelium, were significantly down-regulated in bladder 
biopsies from BPS patients, indicating a compromised tight 
junction structure and possibly increased permeability of the 
urothelium [13]. Therefore it seems possible that urothelial 
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damage is a preceding feature of this disorder and might be 
a causative factor in the pathogenesis of BPS. A decrease 
of E-cadherin mRNA levels, which we observed at mRNA 
level in BPS (Monastyrskaya, unpublished), was confirmed 
by recent findings of lower E-cadherin and ZO-1 expres-
sion in IC/BPS, but not in overactive (OAB) bladders, and 
Fig. 1  Biogenesis of miRNAs. 
Mature microRNAs (miRNAs) 
are approximately 22 nucleo-
tides long and generated by 
a two-step process. The first 
step takes place in the nucleus, 
where primary miRNAs 
(pri-miRNA) are converted 
into precursor miRNAs (pre-
miRNAs) by the microprocessor 
complex containing Drosha and 
DGCR8 (in canonical process) 
or spliceosome, which excises 
the pri-microRNA transcribed 
from introns (in non-canonical 
process). Exportin-5 transports 
pre-miRNAs to the cytoplasm. 
In the second step, the hairpin 
structures of the pre-miRNAs 
are re-cleaved by the RNase 
III Dicer to generate mature 
miRNA. The functional strand 
of the mature miRNA gets 
incorporated into the RNA-
induced Silencing Complex 
RISC (miRISC), where it 
guides miRISC to silence target 
mRNAs through translational 
repression or mRNA cleavage
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suggesting the urothelial barrier function was compromised 
in BPS but not affected in the OAB bladder [53].
BPS is characterized by several other gene expression 
changes: tachykinin receptors NK1R and NK2R were sig-
nificantly down-regulated and bradykinin B1 receptor, can-
nabinoid receptor CB1, and muscarinic receptors M3–M5 
were up-regulated in BPS patients’ biopsies [13]. In addi-
tion, expression of acid-sensing channels, important for 
nociceptive pain, was altered in BPS: we detected an up-
regulation of ASIC2a and ASIC3 mRNA, whereas ASIC1a 
remained unchanged [54]. These changes, in conjunction 
with deficiencies of urothelial barrier, might account for 
increased nociception in BPS patients.
MiRNAs in BPS and OAB
New information is emerging on the miRNA-mediated 
regulation of epithelial permeability, bladder contractility, 
and neurogenic inflammation in bladder dysfunction. While 
studying the gene expression changes characteristic of BPS, 
we observed a perplexing down-regulation of tachykinin 
receptors in the biopsies of BPS patients which prompted 
us to study its mechanisms [13]. Using cell-based models, 
we showed that prolonged exposure of NK1R to Substance 
P (SP) caused a decrease of NK1R mRNA levels and a con-
comitant increase of regulatory miRNAs miR-449b and 
miR-500. In the biopsies of BPS patients, the same miRNAs 
were significantly increased, suggesting that BPS promoted 
an attenuation of NK1R synthesis via activation of specific 
miRNAs. We confirmed this hypothesis by identifying 31 
differentially expressed miRNAs in BPS patients and dem-
onstrated a direct correlation between miR-449b, miR-500, 
miR-328, and miR-320 and a down-regulation of NK1R 
mRNA and/or protein levels. The results of the first miRNA 
profiling in biopsies of BPS patients are shown in Table 1.
Recently, using a mouse model with an induced dele-
tion of Dicer, two groups examined the role of miRNAs in 
the regulation of bladder contractility. An induced smooth-
muscle-specific Dicer knock-out resulted in significantly 
reduced levels of miRNAs, including miR-145, miR-143, 
miR-22, miR-125b-5p, and miR-27a, from detrusor prepa-
rations without mucosa. Deletion of Dicer resulted in a 
disturbed micturition pattern in vivo and reduced depolari-
zation-induced pressure development in an isolated detrusor 
due to decreased levels of L-type Ca2+ channels [55]. In 
a similar study, the loss of Dicer exacerbated cyclophos-
phamide-induced bladder overactivity in mice, possibly 
because the miRNAs capable of targeting P2X mRNAs 
were impaired, leading to enhanced P2X receptor expres-
sion [56]. The authors describe an up-regulation of miR-
34a and miR-25 in the mouse model of OAB. Interestingly, 
miR-25 is also elevated in BPS [13] (Table 1), pointing to 
the similarities of function of this miRNA in both disorders.
Our follow-up study of the miRNA function in BPS 
concerned the role of these molecules in the regulation of 
urothelial permeability [14]. We identified microRNA miR-
199a-5p, which was increased in BPS patients’ biopsies, 
as an important regulator of intercellular junctions. Upon 
overexpression in urothelial cells it impaired correct tight 
junction formation and caused a permeability increase. 
MiR-199a-5p directly targeted mRNAs encoding LIN7C, 
ARHGAP12, PALS1, RND1, and PVRL1 and attenuated 
their expression levels to a similar extent. Laser micro-
dissection revealed that miR-199a-5p was predominantly 
expressed in the bladder smooth muscle, but also detected 
in the mature bladder urothelium and primary urothelial 
cultures. In the urothelium, its expression can be up-reg-
ulated following activation of cAMP signaling pathways. 
Our results point to a possible link between miR-199a-5p 
expression and the control of urothelial permeability in 
bladder pain syndrome. Up-regulation of miR-199a-5p and 
concomitant down-regulation of its multiple targets might 
be detrimental for the establishment of a tight urothelial bar-
rier, leading to chronic pain.
miRNA profiling in bladder cancer (BCa)
Except the studies discussed above, most of the informa-
tion on the role of miRNAs in the bladder comes from the 
work done in BCa. Here we summarize the published data 
in order to identify the organ-specific miRNA expression 
patterns and draw comparisons between BCa and bladder 
dysfunction.
BCa is one of the most common cancers in the world 
[57], the fifth most commonly diagnosed non-cutaneous 
solid malignancy, and, after prostate cancer, the second 
most frequently diagnosed genitourinary tumor [58]. In 
2008, 386,300 new cases of bladder cancers were diagnosed 
globally [59]. The early miRNA screening attempts were 
aimed at defining the cancer-specific miRNAs, and differen-
tiating between the tumor stages by means of miRNA profil-
ing. The first study in human bladder compared the miRNA 
expression profiles of bladder and kidney cancers [60]. Both 
types of cancers were found to share many miRNAs. The 
most significant up-regulated miRNAs in BCa versus nor-
mal bladder (1.2-fold change cutoff; p < 0.05) were: miR-
223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, 
miR-203, miR-17-5p, miR-23a, and miR-205. However, 
this study did not identify any significantly down-regulated 
miRNA in tumors and the data did not overlap with the later 
published results [61], possibly because of the limited num-
ber of reference samples (two normal mucosa).
Expression of 343 miRNA was studied in noninvasive 
and invasive bladder carcinoma cell lines in order to iden-
tify the miRNA signature in BCa suitable for discriminating 
the superficial from the invasive disease [62]. Nine miRNAs 
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with significant differential expression included mir-21, 
mir-31, mir-200a, mir-200c, mir-205, mir-373*, mir-487b, 
mir-498, and mir-503. MiR-21 expression was up-regulated 
and miR-205 down-regulated in the invasive compared with 
the noninvasive bladder cell lines. In 2009, Dyrskjot et al. 
investigated the expression profile of 290 microRNAs in 
immortalized urothelial cell lines, tumorigenic cell lines, 
106 bladder tumors and 11 normal samples and identified 
some differentially expressed miRNAs between cancer and 
normal urothelium. In agreement with the previous study 
[62], miR-21 was the most up-regulated and miR-145 was 
the most down-regulated in cancer compared to the nor-
mal samples. Several differentially expressed miRNAs 
were found comparing different tumor stages. Most sig-
nificant miRNAs up-regulated in progressing tumors were 
miR-129-5p, miR-518c*, miR-185, miR-133b, miR-373*, 
Table 1  Comparative analysis of miRNA expression profiles
Occurrence and regulation of the miRNAs, altered in BPS, BCa bladder cancer, IBD inflammatory bowel disease CD Crohn’s disease, UC ulcer-
ative colitis, asthma, RA rheumatoid arthritis, SLE systemic lupus erythematosus, MS multiple sclerosis and pain
Comparison of miRNA profiles
miRNA BPS BCa IBD (CD, UC) Asthma, RA, MS, SLE Pain
let-7 g Up Up after opioid treatment [109]
Altered in complex regional 
pain syndrome (CRPS) [113]
miR-23a Up Up [60] Up [150] Up in SMC remodeling/ 
asthma [88]
miR-23b Up Up [60] Up [151] Up in SMC remodeling/ 
asthma [88]
Up in neuropathic pain [110]
miR-25 Up Up in SMC remodeling/ 
asthma [88]
miR-26a Up Up in SMC remodeling/ 
asthma [126]
miR-27a Up
miR-30e-5p Up
miR-95 Up
miR-130b Up Down in CRPS [113]
miR-133b Up Up [61],
Down [66]
Up [103] Down after morphine—role in 
pain [152]
miR-148a Down Up in SLE [79]
miR-182 Down
miR-186 Up
miR-192 Up Up [104] Down in CRPS [113]
miR-199a(-5p) Up Down [66] Up [153]
miR-320(a) Up Up [61] Down [151]
miR-324-3p Up Up [103] Down in CRPS [113]
miR-328 Up
miR-342(-3p) Up
miR-379 Up
miR-422a Up Up in MS [94] Down in CRPS [113]
miR-422b(378) Up
miR-449b Up
miR-485-5p Up
miR-493 Down
miR-500(*) Up
miR-502(-5p) Up
miR-511 Up
miR-572 Up Up in MS [94]
miR-594 Up Up [151]
miR-597 Up
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miR-320a, miR-145; and miRNAs, which were mostly 
down-regulated in progressing tumors were miR-29c, miR-
29b, miR-29a, miR-361-5p, miR-203, and miR-205 [61].
Investigation of 322 miRNAs expressed in normal urothe-
lium from patients with high-grade urothelial cell carcino-
mas (UCC) and disease-free controls revealed that 11 % of 
miRNAs were differentially expressed [63]. Down-regula-
tion of miRNAs is a common phenomenon in low-grade 
tumors, and aberrant promoter hyper-methylation influ-
ences miRNA down-regulation in low-grade UCC. Many 
miRNAs down-regulated in low-grade tumors are predicted 
to target FGFR3 (miRs-99a/100/214/145/30a/125b/507). In 
contrast, in high-grade UCC up-regulation of many miR-
NAs including miRNA-21 can suppress p53 function [64].
Lin et al. performed miRNA profiling in BCa and matched 
normal urothelial epithelium controls and identified 37 up-
regulated and 38 down-regulated miRNAs. Among them, 
miRNA-143 was most down-regulated, 13.7 times lower in 
tumor than in the matched control [65]. miRNA-143 was 
not expressed in the human BCa cell lines EJ and T24 and 
its transfection inhibited cell proliferation and reduced RAS 
protein levels [65]. Ichimi et al. investigated tumor-suppres-
sive miRNAs in BCa [66]. Upon screening of 156 miRNAs 
in 14 BCas, five normal bladder epithelium (NBE) sam-
ples and three BCa cell lines, miR-145, miR-30a-3p, miR-
133a, miR-133b, miR-195, miR-125b, and miR-199a* were 
shown to be significantly down-regulated in BCas [66]. Ker-
atin 7 (KRT7) mRNA was a common predicted target for 
the down-regulated miRNAs. Compared to normal bladder 
epithelium, BCa samples had significantly higher mRNA 
levels of KRT 7 [66].
Using microarray technology, Song et al. reported that 
the expression profile of miRNAs was significantly altered 
in bladder urothelial carcinoma tissue compared to adjacent 
normal bladder tissue. Consistent with previous observa-
tions, most differentially expressed miRNAs were down-
regulated. The top ten dis-regulated miRNAs including 
miR-1, miR-145, miR-143, miR-100, miR-200b, miR-708, 
miR-133a, miR-133b, and mir-125b were validated by real-
time RT-PCR [67].
The first report of genome-wide miRNA expression 
profiling in human bladder urothelial carcinoma by deep 
sequencing was published in 2011 by Han et al. [68]. A 
total of 656 differentially expressed miRNAs were detected 
comprising known human miRNAs and miRNA antisense 
sequences (miRNA*s). MiR-490-5p was the most signifi-
cantly down-regulated and miR-96 was the most signifi-
cantly up-regulated miRNA [68].
Notwithstanding a long list of miRNAs de-regulated in 
BCa [69, 70], there is very little overlap in the patterns of 
miRNA expression between BCa and BPS (Table 1), which 
might be indicative of differential organ responses to spe-
cific diseases.
Inflammation in BPS and the role of miRNA  
in immune-mediated diseases
BPS is an inflammatory disorder
Inflammation occurs frequently in the lower urinary tract, and 
most often is a result of a urinary tract infection. One of the 
intriguing features of BPS is the presence of inflammation, 
often confirmed by biopsy, in the absence of an inflammatory 
agent (toxin or microorganism) [71]. Many causative factors 
have been suggested for BPS, including chronic or sub-
clinical infection, autoimmunity and genetic susceptibility, 
which could be responsible for initiating the inflamma-
tory response. However, a central role of inflammation has 
been confirmed in the pathogenesis of interstitial cystitis 
[72]. Epithelial dysfunction, often observed during BPS, 
might cause nerve sensitization, which in turn could lead to 
up-regulation of neurotransmitter release (tachykinins, glu-
tamate, calcitonin gene-related peptide) [73]. Secretion of 
inflammatory mediators such as SP from sensory nerves has 
been implicated in the pathophysiology of pain triggering 
mast cell secretion/neurogenic inflammation [74]. Indeed, 
the obligatory requirement of tachykinin receptor NK1R in 
cystitis and its role in mast cell degranulation and inflam-
mation have been confirmed in experiments with NK1R 
knockout mice [75]. Recently, increased urinary NGF levels 
were described in BPS/IC patients suggesting that chronic 
inflammation is involved in this bladder disorder [76].
A recent study investigated whether bladder inflamma-
tion could directly modulate the apoptotic signaling path-
way in urothelial cells in interstitial cystitis/painful bladder 
syndrome (IC/PBS, equivalent definition of BPS) [77]. The 
levels of pro-apoptotic proteins, including phospho-p53 
(Ser 15), Bad, Bax, and cleaved caspase-3 were significantly 
increased in the IC/PBS bladders. These results suggested 
that the tissue damage and abnormal urothelium in the IC/
PBS bladders might be regulated concurrently by inflamma-
tory signals, such as p38 mitogen-activated protein kinase 
and TNF-alpha. The contents of phospho-p38α and TNF-α 
in IC/PBS samples were significantly greater than in the 
control. The in vitro analysis showed that the apoptotic pro-
cess could be induced by TNF-alpha treatment and aniso-
mycin stimulation in normal urothelial cells [77].
miRNAs as regulators of immune response
During the recent years, plentiful evidence has been amassed 
pointing to the critical role of miRNAs both in the devel-
opment of immune system and its function in innate and 
adaptive responses [78]. Several miRNAs, including miR-155, 
miR-181a, miR-146a, miR-150, miR-223 and miR-17-
92 have been shown to regulate development, differentia-
tion, and function of immune cells (reviewed by [79, 80]). 
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The innate immune response is a cellular response, compris-
ing macrophages, monocytes, granulocytes, and dendritic 
cells, which is started by activation of Toll-like receptors 
(TLR). TLR signaling induces numerous miRNAs includ-
ing miR-155, miR-146a, and miR-21 [81]. Additionally, 
miR-125b and let-7 are important in controlling innate 
immune responses: miR-125b targets TNF-α, while let-7 
targets IL-6 mRNA [82, 83]. Interestingly, although in our 
study we detected an increased neutrophil infiltration in 
the BPS patients [13], none of the classical immune cell-
specific miRNAs were significantly up-regulated. However, 
we detected an increase in miR-500* and miR-511, which 
are important for the dendritic cell, monocyte and mac-
rophage function [84, 85]. These results indicate that the 
elevated miRNAs levels might originate from the bladder 
tissue remodeling during BPS, rather than the immune cell 
infiltration.
Taking into account the role of inflammation in BPS and 
the lack of data on miRNA regulation in the similar inflam-
matory disorders of the bladder, we compared the miRNAs 
identified in other immune-mediated diseases, to the BPS 
profile. These data are summarized in Table 1 and Fig. 2.
Asthma
Asthma is a common chronic airway disease characterized 
by airway remodeling (epithelial alteration, fibrosis, smooth 
muscle hypertrophy) and associated with Th2 response that 
stimulates eosinophile and mast cell infiltration. Asthma is a 
common co-morbidity of BPS [86], therefore we correlated 
the available information on miRNA profiling in this disorder 
with our data in BPS [13]. In the mouse models of asthma, 
miR-1 was down- and miR-21 up-regulated, along with 
21 other differentially expressed miRNAs, and in another 
model, miR-16, -21, and -126 were up-regulated. MiR-133, 
-25, 146a- and -26a regulate human airway smooth muscle 
cells in asthma models (reviewed by [87]). MiR-23a, -23b, 
and -25 play an important role in regulating the phenotype 
of airway smooth muscle via modulating the expression of 
inflammatory mediators like RANTES, eotaxin, and TNF-α. 
These genes are responsible for extracellular matrix turno-
ver and expression of contractile proteins (myosin heavy 
chain) [88]. Interestingly, some of the miRNAs described in 
this study appear to be important in BPS—we found miR-
23a, -23b, -25, and -320 up-regulated in BPS, arguing for 
an increased smooth muscle phenotype, which is consistent 
with low bladder volumes and thick bladder walls observed 
in patients [13].
Autoimmune diseases
The role of miRNAs in autoimmune diseases including 
rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), and multiple sclerosis (MS) has been postulated 
and confirmed by altered levels of several important miR-
NAs (reviewed in [79]). Although no data support a direct 
causal role of autoimmune reactivity in the pathogenesis of 
BPS/IC, there is ample indirect evidence, such as the strong 
female preponderance and the clinical association between 
BPS and other known autoimmune diseases within patients 
and families [15]. BPS is associated with the diagnosis of 
RA [89], SLE, and Sjögren’s syndrome [90]. In RA, miR-
NAs miR-146a, miR-223, and miR-155, characteristic of 
immune cell activation, were significantly up-regulated in 
synovial fluid samples [91]. In MS, miRNAs miR-34a, -155 
and -326 were elevated in active lesions [92]. In SLE, miR-
146a, a negative regulator of TLR signaling was profoundly 
decreased, whereas miR-148a and miR-21 were increased 
in T cells from patients with lupus [93]. Both miR-422a and 
miR-22 have previously been implicated in MS [94]. Taken 
together, miRNA profiling in autoimmune diseases revealed 
a strong prevalence of immune cell-specific miRNAs and 
some overlap with BPS profile established in our study [13].
Inflammatory bowel disease (IBD)
IBD, comprising Crohn’s disease (CD) and ulcerative coli-
tis (UC), is a gastrointestinal chronic inflammatory disorder 
and a frequent co-morbidity of BPS [95]. Earlier work has 
demonstrated that both the number of SP-positive nerve end-
ings and mast cell count were increased in patients with BPS 
and IBD [96], implicating a similar pathogenic mechanism. 
There are numerous reports indicating that patients with CD 
and UC have altered miRNA profiles [97–105]. Analysis of 
miRNA expression in patients with active UC, inactive UC, 
CD, irritable bowel syndrome, infectious colitis, and micro-
scopic colitis revealed eight miRNAs (miR-16, miR-21, 
miR-23a, miR-24, miR-29a, miR-126, miR-195, and Let-7f) 
which were significantly increased in active UC tissues and 
three miRNAs (miR-192, miR-375, and miR-422b) were 
significantly decreased in the UC tissues. Up-regulation of 
0 1 2 3 4 5 6 7 8
MS
SLE
RA
asthma
IBD
bladder cancer
number of miRNAs 
Fig. 2  Similarly regulated miRNAs. Number of miRNAs either up- 
or down-regulated both in BPS and BCa, IBD, RA, SLE, or MS
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Table 2  Validated BPS miRNA targets
miRNA Regulation in BPS Target; function Reference
let-7 g Up 1. Lectin-like oxidized low-density  
lipoprotein receptor-1; inhibition  
of SMC apoptosis
2. Type I collagen alpha2 (COL1A2);  
inhibition of migration
3. μ opioid receptor; role in pain
1. [115]
2. [116]
3. [109]
miR-23a Up 1. Transcription factor Foxo3a; role  
in cardiac hypertrophy
2. Muscle-specific ubiquitin ligases,  
MAFbx/atrogin-1 and muscle  
RING-finger 1 (MuRF1); inhibition  
of muscle atrophy
3. Sprouty2 and Sema6A proteins;  
promote angiogenic activity.
4. E-cadherin
1. [117]
2. [118]
3. [154]
4. [119]
miR-23b Up 1. Smads 3, 4 5; regulation  
of TGF-β signaling
2. FZD7 or MAP3k1;  
metastasis control
3. TAB 2, TAB 3, and IKK-α;  
suppresses IL-17-induced inflammation
1. [121]
2. [120]
3. [122]
miR-25 Up 1. Bim, pro-apoptotic protein;  
increase in proliferation,  
reduction of apoptosis
2. TRAIL Death Receptor-4;  
reduction of apoptosis
1. [124]
2. [125]
miR-26a Up 1. SMAD1, 4; increase SMC  
proliferation, delay differentiation
2. Glycogen synthase kinase GSK-3β;  
smooth muscle hypertrophy
3. Cyclin D2, EZH2; inhibition  
of cancer cell proliferation
1. [126]
2. [127]
3. [155]
miR-27a Up 1. Sprouty2 and Sema6A; enhance angiogenesis
2. Myostatin; role in skeletal muscle proliferation
3. Sprouty 2; enhances proliferation
1. [154]
2. [123]
3 [156].
miR-30e-5p Up No validated targets
miR-95 Up Sorting nexin 1 (SNX1); increases proliferation in  
cancer cells
[129]
miR-130b Up ZEB1; represses EMT in cancer cells
2. RUNX3 apoptotic protein; increase  
cell proliferation
1. [130]
2 [157].
miR-133b Up 1. Pitx3 transcription factor; role in neuron  
differentiation and pain
2. FAIM, GSTP; promotes apoptosis
1. [152]
2. [158]
miR-148a Down 1. ROCK1; increase motility
2. WNT1 and WNT10B; activation  
of WNT/β-catenin pathway
1. [131]
2. [133]
miR-182 Down 1. FOXO1; proliferation
2. CREB1; inhibition of proliferation
1. [159]
2. [160]
miR-186 Up P2X7; Ca homeostasis [134]
miR-192 Up 1. SIP1, Ebox repressor; increase  
of Col1a2 and fibrosis
2. ZEB1/2; increase in fibrosis
1. [135]
2. [136]
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miR-192 was observed in IBD-associated dysplasia [104]. 
UC patients show an up-regulation of immune cell-specific 
miR-21 and miR-155 in inflamed tissue [106].
Comparing active to quiescent UC, it was reported that 
four miRNAs (miR-188-5p, miR-25, miR-320a, miR-346) 
were down-regulated and five miRNA (miR-29a, miR-29b, 
miR-126*, miR-127-3p, miR-324-3p) were up-regulated 
[103]. We found a strong overlap in miRNA expression pro-
files between BPS and IBD (Table 1).
Inflammatory pain disorders
Pain is one of the hallmarks of inflammation, and chronic 
inflammatory conditions are often accompanied by chronic 
pain. Inflammatory pain serves as a warning that hinders 
the normal bodily function until the stimulus abates or the 
tissue repairs. Noxious stimuli activate numerous recep-
tors and ion channels, and signals propagate to the central 
nervous system, where pain is perceived [107]. Epigenetic 
modifications influence inflammatory cytokine metabolism, 
steroid responsiveness, and opioid sensitivity thus contrib-
uting to the development of chronic pain [108], however, 
there are little data implicating miRNA in peripheral pain. 
It was shown that miRNAs might regulate the action of opi-
oid drugs: let-7 miRNA family, including let-7 g, which is 
up-regulated in BPS, was found to be critical for μ opioid 
receptor function. Chronic exposure to morphine caused the 
reduction of MOR levels and concomitant increase in let-7 
miRNA synthesis [109]. It is possible that miRNA induc-
tion might serve as an adaptive response, aimed at reducing 
pain and inflammation: the animals with neuropathic pain 
showed significant improvements after infusion of miR-23b. 
miRNA Regulation in BPS Target; function Reference
miR-199a(-5p) Up 1. Cell junction proteins LIN7C, ARHGAP12,  
PALS1, RND1 and PVRL1; causes  
epithelial dysfunction
2. HIF1alpha, Sirtuin; hypertrophy in  
cardiomyocytes
3. Discoidin domain receptor 1; decrease cancer cell proliferation
1. [14]
2. [161]
3. [162]
miR-320(a) Up 1. β-Catenin; suppresses cancer cell proliferation
2. Neuropilin 1; suppression of cell proliferation
3. Aquaporins 1 and 4; increase of edema
4. NK1R; role in neurogenic inflammation
1. [139]
2. [140]
3. [141]
4. [13]
miR-324-3p Up Prolyl endopeptidase; promotes fibrosis [142]
miR-328 Up 1. NK1R; role in neurogenic inflammation
2. L-type calcium channel a1C, IGFR1; smooth  
muscle remodeling
1. [13]
2. [143]
miR-342(-3p) Up No functional data
miR-379 Up ABCC2 transporter; inhibition of efflux for  
various endogenous and exogenous compounds
[163]
miR-422a Up Tumor suppressor [164]
miR-422b(378) Up 1. IGFR1; cardiac remodeling and decreased survival
2. Sufu (Suppressor of fused) and Fus-1; increased  
cell survival and proliferation
1. [144]
2. [165]
miR-449b Up 1. NK1R; role in neurogenic inflammation
2. CDK6 and CDC25A; cell cycle arrest
1. [13]
2. [145]
miR-485-5p Up No functional data
miR-493 Down 1. FZD4 and RhoC; decrease bladder cancer  
cell growth and migration
2. IGF1R; inhibition of cell growth and metastasis
1. [146]
2. [147]
miR-500(*) Up 1. NK1R; role in neurogenic inflammation
2. Marker of dendritic cells and monocytes,  
regulation of immune response
1 [13].
2. [85]
miR-502(-5p) Up No functional data
miR-511 Up TLR4 and CD80; regulation of immune  
response
[84]
miR-572 Up No functional data
miR-594 Up No functional data
miR-597 Up No functional data
Table 2  continued
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This miRNA down-regulated NADPH oxidase 4 (NOX4), 
a reactive oxygen species (ROS) family member overex-
pressed in neuropathic pain [110].
MiR-124a is expressed in the spinal cord and has been 
implicated in pain. Knock-down of miRNA-124a increased 
the nociceptive behavior via an up-regulation of its pain-
relevant target MeCP2 and proinflammatory marker genes 
[111]. Another recent study identified miR-181a as a modu-
lator of GABA(Aα-1) receptor subunit down-regulation in 
spinal cord following neonatal cystitis-induced chronic vis-
ceral pain in rats [112].
Several miRNAs were profiled from whole blood samples 
of patients with complex regional pain syndrome (CRPS), a 
chronic pain condition resulting from dysfunction of central 
or peripheral nervous systems [113]. Like BPS, CRPS bears 
many signs of neurogenic inflammation. MiRNA profiling 
identified differential expression of 18 miRNAs in CRPS 
patients. Most miRNAs were down-regulated, however 
there is a significant overlap between the miRNAs, altered 
in CRPS and BPS (Table 1).
Functional information on miRNAs, altered in BPS
At the time of miRNA profiling in BPS, very few miRNA 
targets were validated, making it difficult to determine their 
function and potential importance for the disease patho-
genesis. Since then, there has been a surge of publications 
on the miRNA-regulated proteins in cell lines and disease 
states. Sometimes multiple targets have been attributed to 
the same miRNA, implicating it in several, often contradic-
tory, cellular functions. This divergence reflects the pleio-
tropic activity of miRNAs, which are known to regulate 
multiple mRNAs [1, 9]. Nevertheless, out of 31 miRNAs 
from our original study, no targets have been defined for 
miR-30e-5p, miR-342-3p, miR-485-5p, miR-502-5p, miR-
572, miR-594, and miR-597. In contrast, numerous proteins 
have been identified as effectors of miRNAs belonging to 
the well-characterized families like let-7. The information 
on the validated targets of miRNAs altered in BPS is sum-
marized in Table 2 and Fig. 3. Below, we refer in more detail 
to the functional data, relevant for BPS pathogenesis.
Let-7g belongs to the Let-7 family of miRNAs. Let-7 
miRNAs regulate cell differentiation, proliferation, and neu-
romuscular development [16, 114]. The specific functions of 
let-7g include the inhibition of smooth muscle cell (SMC) 
apoptosis by targeting lectin-like oxidized low-density lipo-
protein receptor-1 [115]. Additionally, it targets type I col-
lagen alpha2 (COL1A2) [116], as well as μ opioid receptor, 
and is predicted to have a role in pain perception [109].
miR-23a, -23b, and -27 are members of miR-
23 ∼ 27 ∼ 24 gene cluster. miR-23a is a versatile regulator 
of muscle development and promotes cardiac hypertrophy 
[117]. Ectopic expression of miR-23a was sufficient to pro-
tect muscles from atrophy in vitro and in vivo [118]. In can-
cer cell lines, the expression of miR-23a resulted in inhibi-
tion of E-cadherin expression [119]. Interestingly, we and 
the others have shown a decrease of E-cadherin levels in 
BPS, concomitant with an up-regulation of miR-23a. MiR-
23b has pleiotropic functions in cell proliferation, and has 
been altered in many cancers [120]. It targets and down-
regulates Smads and consequently TGF-beta signaling 
[121]. Recently, an important function of this miRNAs in 
regulation of autoimmune responses has been highlighted: 
miR-23b suppresses IL-17-associated autoimmune inflam-
mation by targeting TGF-β-activated kinase 1/MAP3K7 
binding protein 2 (TAB 2), TAB 3, and inhibitor of nuclear 
factor κ-B kinase subunit α (IKK-α) causing a decrease of 
IL-17-, tumor necrosis factor α (TNF-α)- or IL-1β-induced 
NF-κB activation and inflammatory cytokine expression 
and repression of autoimmune inflammation[122]. miR-
27 plays a role in cell survival, and its overexpression in 
C2C12 cells resulted in myoblast proliferation by reducing 
the expression of myostatin, a critical inhibitor of skeletal 
myogenesis [123].
miR-25 was found up-regulated in BPS and in a mouse 
model of OAB, where it has been suggested to down-reg-
ulate P2X receptors, although the authors did not proceed 
beyond the in silico analysis [56]. miR-25 stimulates cell 
proliferation in ovarian and other cancers [124]. It was 
shown to protect cells against TNF-related apoptosis-induc-
ing ligand (TRAIL)-induced apoptosis [125].
miR-26a is an important regulator of smooth muscle pro-
liferation and function. miR-26a promotes vascular SMC 
proliferation while inhibiting cellular differentiation and 
apoptosis, and alters TGF-β pathway signaling [126]. Over-
expression of miRNA-26a blunted SMC differentiation. 
miRNA-26a influences TGF-β-pathway signaling by target-
ing Smad-1 and Smad-4. Mechanical stretch up-regulates 
miR-26a expression and consequently induces SMC prolif-
eration leading to hypertrophy [127]. miR-26a is a regulator 
of skeletal muscle: it was induced during skeletal muscle 
regeneration and its inhibition de-repressed Smad activity 
and inhibited differentiation [128].
number of miRNAs 
0 2 4 6 8 10 12
pain
cell migration, EMT
 differentiation and remodeling
cell survival and proliferation
inflammaiton, edema, fibrosis
apoptosis
Fig. 3  miRNA functions. Number of miRNAs, altered in BPS and 
associated with a specific function
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miR-95 expression is up-regulated in many tumors. 
Mechanistic studies revealed that miR-95 repressed the 
expression of sorting nexin 1 (SNX1), whereas miR-95 
silencing up-regulated SNX1 expression [129].
miR-130b targets and inhibits transcription factor ZEB1, 
suppressing EMT transition. Its transcription depends on 
p53, and repressed expression of miR-130b triggered ZEB1-
dependent EMT [130].
miR-148a is down-regulated in BPS. Rho-associated 
coiled-coil containing protein kinase 1 (ROCK1) is one 
of its main targets. In skeletal muscle, increase of miR-
148a helps myogenic differentiation through inhibition of 
ROCK1 [131], and in cancer cells it leads to suppressed 
tumor cell invasion and metastasis [132]. Similarly, silenc-
ing miR-148a in cancerous fibroblasts stimulated cell motil-
ity by de-repressing its targets WNT1 and WNT10B and 
activation of WNT/β-catenin pathway [133].
miR-186 was shown to target P2X7 Ca channel, impli-
cated in cell survival and apoptosis [134].
miR-192 is highly expressed in the kidney epithelial 
cells, where it controls TGF-β-induced collagen 1 a2 expres-
sion via down-regulating Smad-interacting protein SIP1, a 
E-box repressor [135]. In a separate study, it was shown to 
increase collagen expression by targeting the E-box repres-
sors Zeb1/2 [136]. Both studies allow concluding that miR-
192 promotes fibrosis.
miR-199a-5p is an important regulator of intercellular 
junctions. Upon overexpression in urothelial cells, it impairs 
correct tight junction formation and leads to increased per-
meability. MiR-199a-5p directly targets mRNAs encod-
ing LIN7C, ARHGAP12, PALS1, RND1 and PVRL1 and 
attenuates their expression levels to a similar extent. It is 
predominantly expressed in the bladder smooth muscle, but 
also detected in the mature bladder urothelium and primary 
urothelial cultures [14].
MiR-199a-5p is up-regulated in cardiac hypertrophy 
and its overexpression in cardiomyocytes leads to cell-size 
increase [137]. A separate study claims that in cultured cell 
lines, the expression of miR-199a and miR-199a* (miR-
199a/a*) is confined to fibroblasts [138].
miR-320a has anti-proliferative effect, which it exerts by 
targeting β-catenin [139], neuropilin 1 (NRP-1), which is a 
co-receptor of vascular epithelial growth factor [140], and 
aquaporins 1 and 4 [141]. We have shown that miR-320a 
down-regulates tachykinin NK1 receptor [13].
miR-324-3p is implicated in the pathogenesis of renal 
fibrosis. A predicted target of miR-324-3p is prolyl endo-
peptidase. In cultured tubular cells, transient transfection 
with a miR-324-3p mimic increased deposition of collagen 
[142].
miR-328 is regulating the NK1R expression levels [13], 
and also has a role in smooth muscle remodeling by target-
ing L-type calcium channel-alpha1C and the insulin growth 
factor 1 receptor expression, ultimately leading to apoptosis 
of pulmonary arterial smooth muscle cells [143].
miR-378 is a cardioabundant microRNA that targets 
IGF1R. In tissues such as fibroblasts and fetal hearts, where 
IGF1 levels are high, there were either absent or signifi-
cantly low miR-378 levels, suggesting an inverse relation-
ship between these two factors [144]. miR-449b, in addition 
to influencing NK1R expression, targets and inhibits onco-
genic CDK6 and CDC25A, resulting in cell-cycle arrest 
[145].
miR-493 is down-regulated in BPS. Interestingly, it has 
been implicated in regulation of bladder cancer tumorigene-
sis: expression of miR-493 in bladder cancer (T24, J82, and 
TCCSUP) cells and tissues was down-regulated. miR-493 
decreased cell growth and migration by reducing the protein 
expression of FZD4 and RhoC [146]. IGF1R was identi-
fied as a direct target of miR-493, and its inhibition partially 
mimicked the anti-metastatic effects [147].
miR-550* was identified by us as a regulator of NK1R 
expression. Recently, it was shown to be specific for plas-
macytoid dendritic cells (pDC) and monocytes [85]. miR-
511 is an important regulator of immune cell function in 
dendritic cells and macrophages: inhibition of the two 
most highly up-regulated miRNAs, miR-511 and miR-99b, 
resulted in reduced lower DC-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) level. Pre-
diction of miRNA-511 targets revealed a number of genes 
with known immune functions, of which TLR4 and CD80 
were validated. Interestingly, under the cell-cycle arrest 
conditions, miR-511 seems to function as a positive regula-
tor of TLR4 [84].
Conclusions and future directions
Here we conducted a comparative analysis of the miRNA 
expression profile in BPS, BCa, and several inflammatory 
disorders, and summarized the validated functional infor-
mation on the differentially expressed miRNAs. Despite the 
existence of several miRNA profiling studies in BCa, we 
found strikingly little overlap between the similarly regu-
lated miRNA species in BCa and BPS.
On the other hand, seven out of 31 miRNA, altered in 
BPS showed the same regulatory pattern in IBD (Table 1, 
Fig. 2). IBD shares many features with BPS, includ-
ing inflammation, pain, smooth muscle remodeling, and 
changes in epithelial permeability [97]. Disruption of epi-
thelial barrier function was identified as one of the patho-
logic mechanisms in IBD, and miR-199a-5p, which we 
have recently characterized as a major regulator of urothe-
lial tight and adherens junctions [14], is also up-regulated 
in IBD patients (Table 1). Similarly, fibrosis is a common 
feature of an advanced inflammatory disease and has been 
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described in both IBD [148] and BPS [149]. Interestingly, 
miR-192, up-regulated in both disorders (Table 1), has vali-
dated targets whose repression leads to increased fibrosis 
(Table 2). Based on this information, it would be interesting 
to take a closer look at these miRNAs in order to determine 
their therapeutic potential.
We found less overlap between BPS miRNAs and miR-
NAs de-regulated in the other inflammatory and autoim-
mune diseases, with the exception of asthma, which shared 
four up-regulated miRNAs. All of them (miR-23a, -23b, -25, 
and -26a) have been implicated in smooth muscle remod-
eling, and some have validated targets among the proteins 
involved in the regulation of muscle growth and differen-
tiation (Table 2). The majority of BPS patients enrolled in 
our study had low-volume thick-walled bladders [13], and 
it would be tempting to speculate on the role of these four 
elevated miRNA in SMC proliferation during BPS.
Some of the functions of the miRNAs altered in BPS 
could be deduced based on the information about their vali-
dated protein targets identified in other cell systems (Fig. 3). 
Due to the pleiotropic nature of miRNAs, the same miRNA 
is often implicated in the regulation of opposing processes, 
i.e., promoting both cell proliferation and apoptosis. Based 
on the data in Table 2, we grouped the miRNAs according 
to their functions (Fig. 3). Most of miRNAs, altered in BPS 
(ten out of 31) have validated targets whose down-regulation 
results in increased apoptosis. These findings fit well with 
the emerging data demonstrating increased apoptosis in 
BPS [77]. The second prominent group was miRNAs influ-
encing inflammation, edema, and fibrosis (nine out of 31). 
We also identified several miRNAs whose targets include 
regulators of cell proliferation and differentiation. It would 
be interesting to determine which bladder layers harbors the 
miRNAs belonging to these functionally opposing groups, 
in order to evaluate the differential effects of inflammation 
on the bladder urothelium and smooth muscle.
MicroRNA research is an exciting and challenging field, 
and we are witness to its burgeoning. Recent years have 
brought about a flood of publications containing both the 
expression profiling and target validation data. Bringing 
these results together yields helpful insights into the miRNA 
function in human diseases and their potential therapeutic 
applications.
Acknowledgments We gratefully acknowledge the financial 
support of the Swiss National Science Foundation (SNF Grant 
320030_135783/1 to K. Monastyrskaya).
References
 1. Bartel DP (2009) MicroRNAs: target recognition and regulatory 
functions. Cell 136(2):215–233. doi:10.1016/j.cell.2009.01.002
 2. Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in 
human cancer. J Pathol 223(2):102–115. doi:10.1002/path.2806
 3. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) 
Identification of novel genes coding for small expressed RNAs. 
Science 294(5543):853–858. doi:10.1126/science.1064921
 4. Orom UA, Nielsen FC, Lund AH (2008) MicroRNA-10a binds the 
5′UTR of ribosomal protein mRNAs and enhances their transla-
tion. Mol Cell 30(4):460–471. doi:10.1016/j.molcel.2008.05.001
 5. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, 
Junemann C, Niepmann M (2008) microRNA-122 stimulates 
translation of hepatitis C virus RNA. EMBO J 27(24):3300–
3310. doi:10.1038/emboj.2008.244
 6. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I (2008) 
MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate 
embryonic stem cell differentiation. Nature 455(7216):1124–
1128. doi:10.1038/nature07299
 7. Huang S, Wu S, Ding J, Lin J, Wei L, Gu J, He X (2010) Micro-
RNA-181a modulates gene expression of zinc finger family 
members by directly targeting their coding regions. Nucleic 
Acids Res 38(20):7211–7218. doi:10.1093/nar/gkq564
 8. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R (2008) 
miR-148 targets human DNMT3b protein coding region. RNA 
14(5):872–877. doi:10.1261/rna.972008
 9. Thomson DW, Bracken CP, Goodall GJ (2011) Experimental 
strategies for microRNA target identification. Nucleic Acids Res 
39(16):6845–6853. doi:10.1093/nar/gkr330
 10. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans hetero-
chronic gene lin-4 encodes small RNAs with antisense comple-
mentarity to lin-14. Cell 75(5):843–854
 11. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q (2008) 
An analysis of human microRNA and disease associations. 
PLoS ONE 3(10):e3420. doi:10.1371/journal.pone.0003420
 12. Wilmott JS, Zhang XD, Hersey P, Scolyer RA (2011) The emerg-
ing important role of microRNAs in the pathogenesis, diagnosis 
and treatment of human cancers. Pathology 43(6):657–671. 
doi:10.1097/PAT.0b013e32834a7358
 13. Sanchez Freire V, Burkhard FC, Kessler TM, Kuhn A, Drae-
ger A, Monastyrskaya K (2010) MicroRNAs may mediate the 
down-regulation of neurokinin-1 receptor in chronic bladder 
pain syndrome. Am J Pathol 176(1):288–303. doi:10.2353/ajp
ath.2010.090552
 14. Monastyrskaya K, Sanchez-Freire V, Gheinani AH, Klumpp DJ, 
Babiychuk EB, Draeger A, Burkhard FC (2012) miR-199a-5p 
regulates urothelial permeability and may play a role in bladder 
pain syndrome. Am J Pathol. doi:10.1016/j.ajpath.2012.10.020
 15. van de Merwe JP (2007) Interstitial cystitis and systemic autoim-
mune diseases. Nat Clin Pract Urol 4(9):484–491. doi:10.1038/n
cpuro0874
 16. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, 
Rougvie AE, Horvitz HR, Ruvkun G (2000) The 21-nucleotide 
let-7 RNA regulates developmental timing in Caenorhabditis 
elegans. Nature 403(6772):901–906. doi:10.1038/35002607
 17. Vasudevan S, Tong Y, Steitz JA (2007) Switching from repres-
sion to activation: microRNAs can up-regulate translation. Sci-
ence 318(5858):1931–1934. doi:10.1126/science.1149460
 18. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R (2008) Micro-
RNA-373 induces expression of genes with complementary pro-
moter sequences. Proc Nat Acad Sci USA 105(5):1608–1613. 
doi:10.1073/pnas.0707594105
 19. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch 
E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, 
Negrini M, Bullrich F, Croce CM (2002) Frequent deletions 
and down-regulation of micro- RNA genes miR15 and miR16 
at 13q14 in chronic lymphocytic leukemia. Proc Nat Acad Sci 
USA 99(24):15524–15529. doi:10.1073/pnas.242606799
3785MicroRNAs in bladder pain and inflammation
1 3
 20. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, 
Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing 
JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expres-
sion profiles classify human cancers. Nature 435(7043):834–
838. doi:10.1038/nature03702
 21. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, 
Gerard RD, Richardson JA, Olson EN (2006) A signature pattern 
of stress-responsive microRNAs that can evoke cardiac hypertro-
phy and heart failure. Proc Nat Acad Sci USA 103(48):18255–
18260. doi:10.1073/pnas.0608791103
 22. Schaefer A, O’Carroll D, Tan CL, Hillman D, Sugimori M, Lli-
nas R, Greengard P (2007) Cerebellar neurodegeneration in the 
absence of microRNAs. J Exp Med 204(7):1553–1558. doi:10.1
084/jem.20070823
 23. Lukiw WJ (2007) Micro-RNA speciation in fetal, adult and Alz-
heimer’s disease hippocampus. NeuroReport 18(3):297–300. 
doi:10.1097/WNR.0b013e3280148e8b
 24. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, 
Hannon G, Abeliovich A (2007) A MicroRNA feedback circuit 
in midbrain dopamine neurons. Science 317(5842):1220–1224. 
doi:10.1126/science.1140481
 25. Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Teng-
vall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius 
A, Stahle M, Pivarcsi A (2007) MicroRNAs: novel regulators 
involved in the pathogenesis of psoriasis? PLoS ONE 2(7):e610. 
doi:10.1371/journal.pone.0000610
 26. Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM, 
Yin YB (2007) Microarray analysis of microRNA expression in 
peripheral blood cells of systemic lupus erythematosus patients. 
Lupus 16(12):939–946. doi:10.1177/0961203307084158
 27. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgom-
ery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson 
M, Clark KR, Mendell JR, Mendell JT (2009) Therapeutic 
microRNA delivery suppresses tumorigenesis in a murine 
liver cancer model. Cell 137(6):1005–1017. doi:10.1016/ 
j.cell.2009.04.021
 28. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, 
Manoharan M, Stoffel M (2005) Silencing of microRNAs in vivo 
with ‘antagomirs’. Nature 438(7068):685–689. doi:10.1038/
nature04303
 29. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lin-
dow M, Munk ME, Kauppinen S, Orum H (2010) Therapeutic 
silencing of microRNA-122 in primates with chronic hepatitis 
C virus infection. Science 327(5962):198–201. doi:10.1126/
science.1178178
 30. Carthew RW, Sontheimer EJ (2009) Origins and mechanisms 
of miRNAs and siRNAs. Cell 136(4):642–655. doi:10.1016/j.
cell.2009.01.035
 31. Chekulaeva M, Filipowicz W (2009) Mechanisms of miRNA-
mediated post-transcriptional regulation in animal cells. Curr 
Opin Cell Biol 21(3):452–460. doi:10.1016/j.ceb.2009.04.009
 32. Kim VN, Han J, Siomi MC (2009) Biogenesis of small 
RNAs in animals. Nat Rev Mol Cell Biol 10(2):126–139. 
doi:10.1038/nrm2632
 33. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) 
Identification of mammalian microRNA host genes and tran-
scription units. Genome Res 14(10A):1902–1910. doi:10.1101
/gr.2722704
 34. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, 
Cooch N, Shiekhattar R (2004) The Microprocessor complex 
mediates the genesis of microRNAs. Nature 432(7014):235–
240. doi:10.1038/nature03120
 35. Wang X, Xu X, Ma Z, Huo Y, Xiao Z, Li Y, Wang Y (2011) 
Dynamic mechanisms for pre-miRNA binding and export by 
Exportin-5. RNA 17(8):1511–1528. doi:10.1261/rna.2732611
 36. MacRae IJ, Zhou K, Doudna JA (2007) Structural determinants 
of RNA recognition and cleavage by Dicer. Nat Struct Mol Biol 
14(10):934–940. doi:10.1038/nsmb1293
 37. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC (2007) The 
mirtron pathway generates microRNA-class regulatory RNAs in 
Drosophila. Cell 130(1):89–100. doi:10.1016/j.cell.2007.06.028
 38. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC (2007) 
Mammalian mirtron genes. Mol Cell 28(2):328–336. 
doi:10.1016/j.molcel.2007.09.028
 39. Ruby JG, Jan CH, Bartel DP (2007) Intronic microRNA precur-
sors that bypass Drosha processing. Nature 448 (7149):83-86. 
http://www.nature.com/nature/journal/v448/n7149/suppinfo/
nature 05983S1.html
 40. Havens MA, Reich AA, Duelli DM, Hastings ML (2012) Bio-
genesis of mammalian microRNAs by a non-canonical process-
ing pathway. Nucleic Acids Res. doi:10.1093/nar/gks026
 41. Kozomara A, Griffiths-Jones S (2011) miRBase: integrating 
microRNA annotation and deep-sequencing data. Nucleic Acids 
Res 39(Database issue):D152–D157. doi:10.1093/nar/gkq1027
 42. Griffiths-Jones S (2004) The microRNA Registry. Nucleic Acids 
Res 32(suppl 1):D109–D111. doi:10.1093/nar/gkh023
 43. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, 
Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin 
P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter 
B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ (2008) Diagnos-
tic criteria, classification, and nomenclature for painful blad-
der syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 
53(1):60–67
 44. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ 
(1999) Epidemiology of interstitial cystitis: a population based 
study. J Urol 161(2):549–552
 45. Fall M, Oberpenning F, Peeker R (2008) Treatment of bladder 
pain syndrome/interstitial cystitis 2008: can we make evidence-
based decisions? Eur Urol 54(1):65–75
 46. Lilly JD, Parsons CL (1990) Bladder surface glycosaminogly-
cans is a human epithelial permeability barrier. Surg Gynecol 
Obstet 171(6):493–496
 47. Moskowitz MO, Byrne DS, Callahan HJ, Parsons CL, Valder-
rama E, Moldwin RM (1994) Decreased expression of a glyco-
protein component of bladder surface mucin (GP1) in interstitial 
cystitis. J Urol 151(2):343–345
 48. Birder LA, de Groat WC (2007) Mechanisms of disease: 
involvement of the urothelium in bladder dysfunction. Nat Clin 
Pract Urol 4(1):46–54. doi:10.1038/ncpuro0672
 49. Parsons CL (2007) The role of the urinary epithelium in the 
pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 
69(4 Suppl):9–16
 50. Tomaszewski JE, Landis JR, Russack V, Williams TM, Wang 
LP, Hardy C, Brensinger C, Matthews YL, Abele ST, Kusek JW, 
Nyberg LM (2001) Biopsy features are associated with primary 
symptoms in interstitial cystitis: results from the interstitial cys-
titis database study. Urology 57(6 Suppl 1):67–81
 51. Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin 
DJ (2004) Abnormal expression of molecular markers for blad-
der impermeability and differentiation in the urothelium of 
patients with interstitial cystitis. J Urol 171(4):1554–1558
 52. Zhang CO, Wang JY, Koch KR, Keay S (2005) Regulation of 
tight junction proteins and bladder epithelial paracellular perme-
ability by an antiproliferative factor from patients with intersti-
tial cystitis. J Urol 174(6):2382–2387
 53. Liu HT, Shie JH, Chen SH, Wang YS, Kuo HC (2012) Dif-
ferences in mast cell infiltration, E-cadherin, and zonula 
occludens-1 expression between patients with overactive blad-
der and interstitial cystitis/bladder pain syndrome. Urology 80 
(1):225 e213-228. doi:10.1016/j.urology.2012.01.047
3786 A. H. Gheinani et al.
1 3
 54. Sanchez-Freire V, Blanchard MG, Burkhard FC, Kessler TM, 
Kellenberger S, Monastyrskaya K (2011) Acid-sensing chan-
nels in human bladder: expression, function and alterations 
during bladder pain syndrome. J Urol 186(4):1509–1516. 
doi:10.1016/j.juro.2011.05.047
 55. Sadegh MK, Ekman M, Rippe C, Uvelius B, Sward K, Albins-
son S (2012) Deletion of Dicer in smooth muscle affects voiding 
pattern and reduces detrusor contractility and neuroeffector  
transmission. PLoS ONE 7(4):e35882. doi:10.1371/journal. 
pone.0035882
 56. Zhang S, Lv JW, Yang P, Yu Q, Pang J, Wang Z, Guo H, Liu S, 
Hu J, Li J, Leng J, Huang Y, Ye Z, Wang CY (2012) Loss of dicer 
exacerbates cyclophosphamide-induced bladder overactivity by 
enhancing purinergic signaling. Am J Pathol 181(3):937–946. 
doi:10.1016/j.ajpath.2012.05.035
 57. Zhu J, Jiang Z, Gao F, Hu X, Zhou L, Chen J, Luo H, Sun J, Wu 
S, Han Y, Yin G, Chen M, Han Z, Li X, Huang Y, Zhang W, Zhou 
F, Chen T, Fa P, Wang Y, Sun L, Leng H, Sun F, Liu Y, Ye M, 
Yang H, Cai Z, Gui Y, Zhang X (2011) A systematic analysis on 
dna methylation and the expression of both mRNA and micro-
RNA in bladder cancer. PLoS ONE 6(11):e28223. doi:10.1371/
journal.pone.0028223
 58. Theodorescu D (2003) Molecular pathogenesis of urothelial 
bladder cancer. Histol Histopathol 18(1):259–274
 59. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D 
(2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. 
doi:10.3322/caac.20107
 60. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi 
P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella 
LG, Croce CM, Baffa R (2007) Micro-RNA profiling in 
kidney and bladder cancers. Urol Oncol 25(5):387–392. 
doi:10.1016/j.urolonc.2007.01.019
 61. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy 
P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger 
K, Kauppinen S, Ulhoi BP, Kjems J, Borre M, Orntoft TF (2009) 
Genomic profiling of microRNAs in bladder cancer: miR-129 
is associated with poor outcome and promotes cell death in 
vitro. Cancer Res 69(11):4851–4860. doi:10.1158/0008-5472.
CAN-08-4043
 62. Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, 
Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, 
Summerhayes IC (2008) A microRNA expression ratio defining 
the invasive phenotype in bladder tumors. Urol Oncol 28(1):39–
48. doi:10.1016/j.urolonc.2008.06.006
 63. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, 
Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles 
MA, Meuth M, Harris AL, Hamdy FC (2009) Distinct micro-
RNA alterations characterize high- and low-grade bladder can-
cer. Cancer Res 69(21):8472–8481. doi:10.1158/0008-5472.
CAN-09-0744
 64. Ayala de la Pena F, Kanasaki K, Kanasaki M, Tangirala N, Maeda 
G, Kalluri R (2011) Loss of p53 and acquisition of angiogenic 
microRNA profile are insufficient to facilitate progression of 
bladder urothelial carcinoma in situ to invasive carcinoma. J Biol 
Chem 286(23):20778–20787. doi:10.1074/jbc.M110.198069
 65. Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L 
(2009) MicroRNA-143 as a tumor suppressor for bladder cancer. 
J Urol 181(3):1372–1380. doi:10.1016/j.juro.2008.10.149
 66. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, 
Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama 
K, Tsujimoto G, Nakagawa M, Seki N (2009) Identification of 
novel microRNA targets based on microRNA signatures in blad-
der cancer. Int J Cancer 125(2):345–352. doi:10.1002/ijc.24390
 67. Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, 
Li H (2010) Differential miRNA expression profiles in bladder 
urothelial carcinomas. Asian Pac J Cancer Prev 11(4):905–911
 68. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang 
Z, Yang R, Li Z, Tang A, Li X, Ye J, Guan Z, Gui Y, Cai Z (2011) 
MicroRNA expression signatures of bladder cancer revealed 
by deep sequencing. PLoS ONE 6(3):e18286. doi:10.1371/
journal.pone.0018286
 69. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, 
Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, 
Visakorpi T (2011) MicroRNA in prostate, bladder, and kid-
ney cancer: a systematic review. Eur Urol 59(5):671–681. 
doi:10.1016/j.eururo.2011.01.044
 70. Ru Y, Dancik GM, Theodorescu D (2011) Biomarkers for 
prognosis and treatment selection in advanced bladder cancer 
patients. Curr Opin Urol 21(5):420–427. doi:10.1097/MOU.0b0
13e32834956d6
 71. Wyndaele JJ, Van Dyck J, Toussaint N (2009) Cystoscopy and 
bladder biopsies in patients with bladder pain syndrome car-
ried out following ESSIC guidelines. Scand J Urol Nephrol 
43(6):471–475. doi:10.3109/00365590903199007
 72. Grover S, Srivastava A, Lee R, Tewari AK, Te AE (2011) Role 
of inflammation in bladder function and interstitial cystitis. Ther 
Adv Urol 3(1):19–33. doi:10.1177/1756287211398255
 73. Keay S (2008) Cell signaling in interstitial cystitis/pain-
ful bladder syndrome. Cell Signal 20(12):2174–2179. 
doi:10.1016/j.cellsig.2008.06.004
 74. Pang X, Marchand J, Sant GR, Kream RM, Theoharides TC 
(1995) Increased number of substance P positive nerve fibres in 
interstitial cystitis. Br J Urol 75(6):744–750
 75. Saban R, Saban MR, Nguyen NB, Lu B, Gerard C, Gerard NP, 
Hammond TG (2000) Neurokinin-1 (NK-1) receptor is required 
in antigen-induced cystitis. Am J Pathol 156(3):775–780. 
doi:10.1016/S0002-9440(10)64944-9
 76. Liu HT, Kuo HC (2012) Increased urine and serum nerve growth 
factor levels in interstitial cystitis suggest chronic inflamma-
tion is involved in the pathogenesis of disease. PLoS ONE 
7(9):e44687. doi:10.1371/journal.pone.0044687
 77. Shie JH, Liu HT, Kuo HC (2012) Increased cell apoptosis of 
urothelium mediated by inflammation in interstitial cystitis/
painful bladder syndrome. Urology 79 (2):484 e487-413. 
doi:10.1016/j.urology.2011.09.049
 78. O’Connell RM, Rao DS, Baltimore D (2012) microRNA regu-
lation of inflammatory responses. Annu Rev Immunol 30:295–
312. doi:10.1146/annurev-immunol-020711-075013
 79. Dai R, Ahmed SA (2011) MicroRNA, a new paradigm for 
understanding immunoregulation, inflammation, and autoim-
mune diseases. Transl Res 157(4):163–179. doi:10.1016/j.trsl. 
2011.01.007
 80. Tomankova T, Petrek M, Gallo J, Kriegova E (2011) MicroR-
NAs: emerging regulators of immune-mediated diseases. Scand 
J Immunol. doi:10.1111/j.1365-3083.2011.02650.x
 81. O’Neill LA, Sheedy FJ, McCoy CE (2011) MicroRNAs: the 
fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 
11(3):163–175. doi:10.1038/nri2957
 82. Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch 
involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links 
inflammation to cell transformation. Cell 139(4):693–706. 
doi:10.1016/j.cell.2009.10.014
 83. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, 
Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM 
(2007) Modulation of miR-155 and miR-125b levels following 
lipopolysaccharide/TNF-alpha stimulation and their possible 
roles in regulating the response to endotoxin shock. J Immunol 
179(8):5082–5089
 84. Tserel L, Runnel T, Kisand K, Pihlap M, Bakhoff L, Kolde R, 
Peterson H, Vilo J, Peterson P, Rebane A (2011) MicroRNA 
expression profiles of human blood monocyte-derived dendritic 
cells and macrophages reveal miR-511 as putative positive 
3787MicroRNAs in bladder pain and inflammation
1 3
regulator of Toll-like receptor 4. J Biol Chem 286(30):26487–
26495. doi:10.1074/jbc.M110.213561
 85. Allantaz F, Cheng DT, Bergauer T, Ravindran P, Rossier MF, 
Ebeling M, Badi L, Reis B, Bitter H, D’Asaro M, Chiappe 
A, Sridhar S, Pacheco GD, Burczynski ME, Hochstrasser D, 
Vonderscher J, Matthes T (2012) Expression profiling of human 
immune cell subsets identifies miRNA-mRNA regulatory rela-
tionships correlated with cell type specific expression. PLoS 
ONE 7(1):e29979. doi:10.1371/journal.pone.0029979
 86. Keller JJ, Chen YK, Lin HC (2012) Comorbidities of bladder 
pain syndrome/interstitial cystitis: a population-based study. 
BJU Int. doi:10.1111/j.1464-410X.2012.11539.x
 87. Jiang X (2011) The emerging role of microRNAs in asthma. Mol 
Cell Biochem 353(1–2):35–40. doi:10.1007/s11010-011-0771-z
 88. Kuhn AR, Schlauch K, Lao R, Halayko AJ, Gerthoffer WT, 
Singer CA (2010) MicroRNA expression in human airway 
smooth muscle cells: role of miR-25 in regulation of airway 
smooth muscle phenotype. Am J Resp Cell Mol Biol 42(4):506–
513. doi:10.1165/rcmb.2009-0123OC
 89. Keller JJ, Liu SP, Lin HC (2012) A case-control study on the asso-
ciation between rheumatoid arthritis and bladder pain syndrome/
interstitial cystitis. Neurourol Urodyn. doi:10.1002/nau.22348
 90. van de Merwe JP, Yamada T, Sakamoto Y (2003) Systemic 
aspects of interstitial cystitis, immunology and linkage with 
autoimmune disorders. Int J Urol 10(Suppl):S35–S38
 91. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, 
Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski 
B, McSharry C, Hueber AJ, Baxter D, Hunter J, Gay S, Liew 
FY, McInnes IB (2011) MicroRNA-155 as a proinflammatory 
regulator in clinical and experimental arthritis. Proc Natl Acad 
Sci USA 108(27):11193–11198. doi:10.1073/pnas.1019536108
 92. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei 
G (2009) MicroRNA miR-326 regulates TH-17 differentiation 
and is associated with the pathogenesis of multiple sclerosis. Nat 
Immunol 10(12):1252–1259. doi:10.1038/ni.1798
 93. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, 
de Vries N, Tak PP, Chen S, Shen N (2009) MicroRNA-146A 
contributes to abnormal activation of the type I interferon path-
way in human lupus by targeting the key signaling proteins. 
Arthritis Rheum 60(4):1065–1075. doi:10.1002/art.24436
 94. Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Grif-
fiths L (2012) Circulating microRNAs involved in multi-
ple sclerosis. Mol Biol Rep 39(5):6219–6225. doi:10.1007/
s11033-011-1441-7
 95. Chelimsky G, Heller E, Buffington CA, Rackley R, Zhang D, 
Chelimsky T (2012) Co-morbidities of interstitial cystitis. Front 
Neurosci 6:114. doi:10.3389/fnins.2012.00114
 96. Pang X, Boucher W, Triadafilopoulos G, Sant GR, Theo-
harides TC (1996) Mast cell and substance P-positive nerve 
involvement in a patient with both irritable bowel syndrome 
and interstitial cystitis. Urology 47(3):436–438. doi:10.1016/
s0090-4295(99)80469-5
 97. Pekow JR, Kwon JH (2012) MicroRNAs in inflamma-
tory bowel disease. Inflamm Bowel Dis 18(1):187–193. 
doi:10.1002/ibd.21691
 98. Iborra M, Bernuzzi F, Invernizzi P, Danese S (2012) MicroR-
NAs in autoimmunity and inflammatory bowel disease: crucial 
regulators in immune response. Autoimmun Rev 11(5):305–314. 
doi:10.1016/j.autrev.2010.07.002
 99. Paraskevi A, Theodoropoulos G, Papaconstantinou I, Man-
tzaris G, Nikiteas N, Gazouli M (2012) Circulating Micro-
RNA in inflammatory bowel disease. J Crohns Colitis. 
doi:10.1016/j.crohns.2012.02.006
 100. Zwiers A, Kraal L, van de Pouw Kraan TC, Wurdinger T, Bouma 
G, Kraal G (2012) Cutting edge: a variant of the IL-23R gene 
associated with inflammatory bowel disease induces loss of 
microRNA regulation and enhanced protein production. J Immu-
nol 188(4):1573–1577. doi:10.4049/jimmunol.1101494
 101. Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, 
Weller C, Cohen E, Roberts H, Keskey B, Petras RE, Crawford 
NP, Galandiuk S (2012) Differential microRNA expression tracks 
neoplastic progression in inflammatory bowel disease-associ-
ated colorectal cancer. Hum Mutat 33(3):551–560. doi:10.1002/ 
humu.22021
 102. Dalal SR, Kwon JH (2010) The role of microRNA in inflamma-
tory bowel disease. Gastroenterol Hepatol (NY) 6(11):714–722
 103. Fasseu M, Treton X, Guichard C, Pedruzzi E, Cazals-Hatem D, 
Richard C, Aparicio T, Daniel F, Soule JC, Moreau R, Bouhnik 
Y, Laburthe M, Groyer A, Ogier-Denis E (2010) Identification 
of restricted subsets of mature microRNA abnormally expressed 
in inactive colonic mucosa of patients with inflammatory bowel 
disease. PLoS One 5 (10). doi:10.1371/journal.pone.0013160
 104. Olaru AV, Selaru FM, Mori Y, Vazquez C, David S, Paun B, 
Cheng Y, Jin Z, Yang J, Agarwal R, Abraham JM, Dassopoulos 
T, Harris M, Bayless TM, Kwon J, Harpaz N, Livak F, Meltzer 
SJ (2011) Dynamic changes in the expression of MicroRNA-31 
during inflammatory bowel disease-associated neoplastic trans-
formation. Inflamm Bowel Dis 17(1):221–231. doi:10.1002/ 
ibd.21359
 105. Clark PM, Dawany N, Dampier W, Byers SW, Pestell RG, Toz-
eren A (2012) Bioinformatics analysis reveals transcriptome and 
microRNA signatures and drug repositioning targets for IBD and 
other autoimmune diseases. Inflamm Bowel Dis 18(12):2315–
2333. doi:10.1002/ibd.22958
 106. Takagi T, Naito Y, Mizushima K, Hirata I, Yagi N, Tomatsuri N, 
Ando T, Oyamada Y, Isozaki Y, Hongo H, Uchiyama K, Handa 
O, Kokura S, Ichikawa H, Yoshikawa T (2010) Increased expres-
sion of microRNA in the inflamed colonic mucosa of patients 
with active ulcerative colitis. J Gastroenterol Hepatol 25(Suppl 
1):S129–S133. doi:10.1111/j.1440-1746.2009.06216.x
 107. Bingham B, Ajit SK, Blake DR, Samad TA (2009) The molecular 
basis of pain and its clinical implications in rheumatology. Nat 
Clin Pract Rheumatol 5(1):28–37. doi:10.1038/ncprheum0972
 108. Buchheit T, Van de Ven T, Shaw A (2012) Epigenetics 
and the transition from acute to chronic pain. Pain Med. 
doi:10.1111/j.1526-4637.2012.01488.x
 109. He Y, Wang ZJ (2012) Let-7 microRNAs and Opioid Tolerance. 
Front Genet 3:110. doi:10.3389/fgene.2012.00110
 110. Im YB, Jee MK, Jung JS, Choi JI, Jang JH, Kang SK (2012) 
miR23b ameliorates neuropathic pain in spinal cord by silencing 
NADPH oxidase 4. Antioxid Redox Signal 16(10):1046–1060. 
doi:10.1089/ars.2011.4224
 111. Kynast KL, Russe OQ, Moser CV, Geisslinger G, Niederberger 
E (2012) Modulation of central nervous system-specific micro-
RNA-124a alters the inflammatory response in the formalin test 
in mice. Pain. doi:10.1016/j.pain.2012.11.010
 112. Sengupta JN, Pochiraju S, Kannampalli P, Bruckert M, Addya 
S, Yadav P, Miranda A, Shaker R, Banerjee B (2013) Micro-
RNA-mediated GABA(Aalpha-1) receptor subunit down-regu-
lation in adult spinal cord following neonatal cystitis-induced 
chronic visceral pain in rats. Pain 154(1):59–70. doi:10.1016/j.
pain.2012.09.002
 113. Orlova IA, Alexander GM, Qureshi RA, Sacan A, Graziano A, 
Barrett JE, Schwartzman RJ, Ajit SK (2011) MicroRNA modu-
lation in complex regional pain syndrome. J Transl Med 9:195. 
doi:10.1186/1479-5876-9-195
 114. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda 
MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, 
Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine 
M, Leahy P, Davidson E, Ruvkun G (2000) Conservation of the 
sequence and temporal expression of let-7 heterochronic regula-
tory RNA. Nature 408(6808):86–89. doi:10.1038/35040556
3788 A. H. Gheinani et al.
1 3
 115. Ding Z, Wang X, Khaidakov M, Liu S, Mehta JL (2012) Micro-
RNA hsa-let-7 g targets lectin-like oxidized low-density lipo-
protein receptor-1 expression and inhibits apoptosis in human 
smooth muscle cells. Exp Biol Med (Maywood) 237(9):1093–
1100. doi:10.1258/ebm.2012.012082
 116. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, 
Shi X, Tang ZY, Wang XW (2010) Let-7 g targets collagen type 
I alpha2 and inhibits cell migration in hepatocellular carcinoma. 
J Hepatol 52(5):690–697. doi:10.1016/j.jhep.2009.12.025
 117. Wang K, Lin ZQ, Long B, Li JH, Zhou J, Li PF (2012) Cardiac 
hypertrophy is positively regulated by MicroRNA miR-23a. J 
Biol Chem 287(1):589–599. doi:10.1074/jbc.M111.266940
 118. Wada S, Kato Y, Okutsu M, Miyaki S, Suzuki K, Yan Z, Schi-
affino S, Asahara H, Ushida T, Akimoto T (2011) Transla-
tional suppression of atrophic regulators by microRNA-23a 
integrates resistance to skeletal muscle atrophy. J Biol Chem 
286(44):38456–38465. doi:10.1074/jbc.M111.271270
 119. Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi 
Y, Noro R, Yoshimura A, Cai L, Gemma A (2012) MiR-23a reg-
ulates TGF-beta-induced epithelial-mesenchymal transition by 
targeting E-cadherin in lung cancer cells. Int J Oncol 41(3):869–
875. doi:10.3892/ijo.2012.1535
 120. Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin S, Sun C, Ma M, 
Huang Y, Xi JJ (2011) Genome-wide functional screening of 
miR-23b as a pleiotropic modulator suppressing cancer metas-
tasis. Nat Commun 2:554. doi:10.1038/ncomms1555
 121. Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T, 
Norel R, Rogler LE (2009) MicroRNA-23b cluster microRNAs 
regulate transforming growth factor-beta/bone morphogenetic 
protein signaling and liver stem cell differentiation by targeting 
Smads. Hepatology 50(2):575–584. doi:10.1002/hep.22982
 122. Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, Liang D, He D, 
Wang H, Liu W, Shi Y, Harley JB, Shen N, Qian Y (2012) The 
microRNA miR-23b suppresses IL-17-associated autoimmune 
inflammation by targeting TAB 2, TAB 3 and IKK-alpha. Nat 
Med 18(7):1077–1086. doi:10.1038/nm.2815
 123. Huang Z, Chen X, Yu B, He J, Chen D (2012) MicroRNA-
27a promotes myoblast proliferation by targeting myosta-
tin. Biochem Biophys Res Commun 423(2):265–269. 
doi:10.1016/j.bbrc.2012.05.106
 124. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z (2012) MiR-25 
regulates apoptosis by targeting Bim in human ovarian cancer. 
Oncol Rep 27(2):594–598. doi:10.3892/or.2011.1530
 125. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg 
NW, Roberts LR, Mott JL (2012) miR-25 targets TNF-related 
apoptosis inducing ligand (TRAIL) death receptor-4 and pro-
motes apoptosis resistance in cholangiocarcinoma. Hepatology 
55(2):465–475. doi:10.1002/hep.24698
 126. Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Mae-
gdefessel L, Kundu RK, Quertermous T, Tsao PS, Spin JM 
(2011) MicroRNA-26a is a novel regulator of vascular smooth 
muscle cell function. J Cell Physiol 226(4):1035–1043. 
doi:10.1002/jcp.22422
 127. Mohamed JS, Lopez MA, Boriek AM (2010) Mechanical stretch 
up-regulates microRNA-26a and induces human airway smooth 
muscle hypertrophy by suppressing glycogen synthase kinase-
3beta. J Biol Chem 285(38):29336–29347. doi:10.1074/jbc.
M110.101147
 128. Dey BK, Gagan J, Yan Z, Dutta A (2012) miR-26a is required for 
skeletal muscle differentiation and regeneration in mice. Genes 
Dev 26(19):2180–2191. doi:10.1101/gad.198085.112
 129. Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, Sheng 
W, He X, Du X (2011) MicroRNA-95 promotes cell prolif-
eration and targets sorting Nexin 1 in human colorectal carci-
noma. Cancer Res 71(7):2582–2589. doi:10.1158/0008-5472. 
can-10-3032
 130. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari 
H, Sudo S, Ju J, Sakuragi N (2012) Mutant p53 gain-of-func-
tion induces epithelial-mesenchymal transition through modu-
lation of the miR-130b-ZEB1 axis. Oncogene. doi:10.1038/
onc.2012.334
 131. Zhang J, Ying ZZ, Tang ZL, Long LQ, Li K (2012) MicroRNA-
148a promotes myogenic differentiation by targeting the ROCK1 
gene. J Biol Chem 287(25):21093–21101. doi:10.1074/jbc.
M111.330381
 132. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia 
D, Tian Q, Wu J, Ye Y, Wang Q, Long Z, Zhou Y, Du C, He X, Shi 
Y (2011) MicroRNA-148a suppresses tumor cell invasion and 
metastasis by downregulating ROCK1 in gastric cancer. Clin Can-
cer Res 17(24):7574–7583. doi:10.1158/1078-0432.ccr-11-1714
 133. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens 
R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber 
J (2012) Silencing of miR-148a in cancer-associated fibroblasts 
results in WNT10B-mediated stimulation of tumor cell motility. 
Oncogene. doi:10.1038/onc.2012.351
 134. Zhou L, Qi X, Potashkin JA, Abdul-Karim FW, Gorodeski 
GI (2008) MicroRNAs miR-186 and miR-150 down-regulate 
expression of the pro-apoptotic purinergic P2X7 receptor by 
activation of instability sites at the 3′-untranslated region of the 
gene that decrease steady-state levels of the transcript. J Biol 
Chem 283(42):28274–28286. doi:10.1074/jbc.M802663200
 135. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, Nata-
rajan R (2007) MicroRNA-192 in diabetic kidney glomeruli and 
its function in TGF-beta-induced collagen expression via inhibi-
tion of E-box repressors. Proc Natl Acad Sci USA 104(9):3432–
3437. doi:10.1073/pnas.0611192104
 136. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R (2012) 
Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic 
nephropathy. J Am Soc Nephrol 23(3):458–469. doi:10.1681/ 
asn.2011050485
 137. Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, Ren AJ, 
Wang YR, Qin YW, Yuan WJ, Jing Q (2010) MicroRNAs are 
dynamically regulated in hypertrophic hearts, and miR-199a is 
essential for the maintenance of cell size in cardiomyocytes. J 
Cell Physiol 225(2):437–443. doi:10.1002/jcp.22217
 138. Kim S, Lee UJ, Kim MN, Lee EJ, Kim JY, Lee MY, Choung S, 
Kim YJ, Choi YC (2008) MicroRNA miR-199a* regulates the 
MET proto-oncogene and the downstream extracellular signal-
regulated kinase 2 (ERK2). J Biol Chem 283(26):18158–18166. 
doi:10.1074/jbc.M800186200
 139. Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, Yan B, 
Bian YQ, Zhao J, Wang WZ, Yang AG, Zhang R (2012) Micro-
RNA-320a suppresses human colon cancer cell proliferation by 
directly targeting beta-catenin. Biochem Biophys Res Commun 
420(4):787–792. doi:10.1016/j.bbrc.2012.03.075
 140. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, Zhang Q, Dong 
L, Dong J (2012) microRNA-320a inhibits tumor invasion by 
targeting neuropilin 1 and is associated with liver metastasis 
in colorectal cancer. Oncol Rep 27(3):685–694. doi:10.3892/
or.2011.1561
 141. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swami-
nathan P, Tan JR, Jeyaseelan K (2010) MicroRNA 320a func-
tions as a novel endogenous modulator of aquaporins 1 and 4 as 
well as a potential therapeutic target in cerebral ischemia. J Biol 
Chem 285(38):29223–29230. doi:10.1074/jbc.M110.144576
 142. Macconi D, Tomasoni S, Romagnani P, Trionfini P, Sangalli F, 
Mazzinghi B, Rizzo P, Lazzeri E, Abbate M, Remuzzi G, Benigni 
A (2012) MicroRNA-324-3p Promotes Renal Fibrosis and Is a 
Target of ACE Inhibition. J Am Soc Nephrol 23(9):1496–1505. 
doi:10.1681/asn.2011121144
 143. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S, Tian H, Jiang C, 
Zhu D (2012) The microRNA-328 regulates hypoxic pulmonary 
3789MicroRNAs in bladder pain and inflammation
1 3
hypertension by targeting at insulin growth factor 1 receptor and 
L-type calcium channel-alpha1C. Hypertension 59(5):1006–
1013. doi:10.1161/hypertensionaha.111.185413
 144. Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, 
Nagalingam RS, Gupta M (2012) A novel cardiomyocyte-
enriched microRNA, miR-378, targets insulin-like growth factor 
1 receptor: implications in postnatal cardiac remodeling and cell 
survival. J Biol Chem 287(16):12913–12926. doi:10.1074/jbc.
M111.331751
 145. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q (2009) miR-
449a and miR-449b are direct transcriptional targets of E2F1 
and negatively regulate pRb-E2F1 activity through a feedback 
loop by targeting CDK6 and CDC25A. Genes Dev 23(20):2388–
2393. doi:10.1101/gad.1819009
 146. Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai 
ZL, Hinoda Y, Dahiya R (2012) Tumor suppressor microRNA-493 
decreases cell motility and migration ability in human bladder 
cancer cells by downregulating RhoC and FZD4. Mol Cancer 
Ther 11(1):244–253. doi:10.1158/1535-7163.mct-11-0592
 147. Okamoto K, Ishiguro T, Midorikawa Y, Ohata H, Izumiya M, 
Tsuchiya N, Sato A, Sakai H, Nakagama H (2012) miR-493 
induction during carcinogenesis blocks metastatic settlement of 
colon cancer cells in liver. EMBO J 31(7):1752–1763. doi:10.10
38/emboj.2012.25
 148. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler 
TM, Gopalan B, Stylianou E, Fiocchi C (2011) Inflammation-
induced endothelial-to-mesenchymal transition: a novel mech-
anism of intestinal fibrosis. Am J Pathol 179(5):2660–2673. 
doi:10.1016/j.ajpath.2011.07.042
 149. Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn 
T, Hansen AB (2010) YKL-40 and mast cells are associated with 
detrusor fibrosis in patients diagnosed with bladder pain syn-
drome/interstitial cystitis according to the 2008 criteria of the 
European Society for the Study of Interstitial Cystitis. Histopa-
thology 57(3):371–383. doi:10.1111/j.1365-2559.2010.03640.x
 150. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bay-
less TM, Brant SR, Chakravarti S, Kwon JH (2008) MicroRNAs 
are differentially expressed in ulcerative colitis and alter expres-
sion of macrophage inflammatory peptide-2 alpha. Gastroenterol-
ogy 135 (5):1624-1635 e1624. doi:10.1053/j.gastro.2008.07.068
 151. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Melt-
zer SJ, Brant SR, Kwon JH (2010) Identification of microRNAs 
associated with ileal and colonic Crohn’s disease. Inflamm 
Bowel Dis 16(10):1729–1738. doi:10.1002/ibd.21267
 152. Sanchez-Simon FM, Zhang XX, Loh HH, Law PY, Rodriguez 
RE (2010) Morphine regulates dopaminergic neuron differentia-
tion via miR-133b. Mol Pharmacol 78(5):935–942. doi:10.1124/
mol.110.066837
 153. Wu F, Guo NJ, Tian H, Marohn M, Gearhart S, Bayless TM, 
Brant SR, Kwon JH (2011) Peripheral blood microRNAs dis-
tinguish active ulcerative colitis and Crohn’s disease. Inflamm 
Bowel Dis 17(1):241–250. doi:10.1002/ibd.21450
 154. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, 
Wang S (2011) Regulation of angiogenesis and choroidal neo-
vascularization by members of microRNA-23~27~24 clusters. 
Proc Natl Acad Sci USA 108(20):8287–8292. doi:10.1073/p
nas.1105254108
 155. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng 
Y, Yao KT, Kung HF, Li XP (2011) MiR-26a inhibits cell growth 
and tumorigenesis of nasopharyngeal carcinoma through repres-
sion of EZH2. Cancer Res 71(1):225–233. doi:10.1158/0008-
5472.can-10-1850
 156. Ma Y, Yu S, Zhao W, Lu Z, Chen J (2010) miR-27a regulates 
the growth, colony formation and migration of pancreatic can-
cer cells by targeting Sprouty2. Cancer Lett 298(2):150–158. 
doi:10.1016/j.canlet.2010.06.012
 157. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim 
XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, Soong 
R (2010) MicroRNA-130b regulates the tumour suppres-
sor RUNX3 in gastric cancer. Eur J Cancer 46(8):1456–1463. 
doi:10.1016/j.ejca.2010.01.036
 158. Patron JP, Fendler A, Bild M, Jung U, Muller H, Arntzen MO, 
Piso C, Stephan C, Thiede B, Mollenkopf HJ, Jung K, Kauf-
mann SH, Schreiber J (2012) MiR-133b targets antiapoptotic 
genes and enhances death receptor-induced apoptosis. PLoS 
ONE 7(4):e35345. doi:10.1371/journal.pone.0035345
 159. Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbin-
ger J, Pelzer C, Vogel MJ, Maier HJ, Gascoyne RD, Moller 
P, Wirth T (2012) FOXO1 is a tumor suppressor in classical 
Hodgkin lymphoma. Blood 119(15):3503–3511. doi:10.1182/
blood-2011-09-381905
 160. Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, Tang H (2012) 
MicroRNA-182 targets cAMP-responsive element-bind-
ing protein 1 and suppresses cell growth in human gastric 
adenocarcinoma. FEBS J 279(7):1252–1260. doi:10.1111/ 
j.1742-4658.2012.08519.x
 161. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima 
J, Vatner DE, Vatner SF, Abdellatif M (2009) Downregulation 
of miR-199a derepresses hypoxia-inducible factor-1 alpha and 
Sirtuin 1 and recapitulates hypoxia preconditioning in car-
diac myocytes. Circ Res 104(7):879–886. doi:10.1161/circres
aha.108.193102
 162. Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos 
GC, Radtke A, Lu M, Paul A, Gerken G, Beckebaum S (2010) 
Role of microRNA-199a-5p and discoidin domain receptor 1 in 
human hepatocellular carcinoma invasion. Mol Cancer 9:227. 
doi:10.1186/1476-4598-9-227
 163. Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, 
Bruhn O, Remmler C, Cascorbi I (2011) Down-regulation of 
ATP-binding cassette C2 protein expression in HepG2 cells after 
rifampicin treatment is mediated by microRNA-379. Mol Phar-
macol 80(2):314–320. doi:10.1124/mol.110.070714
 164. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, 
Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, 
Slaby O (2012) Identification and functional screening of micro-
RNAs highly deregulated in colorectal cancer. J Cell Mol Med 
16(11):2655–2666. doi:10.1111/j.1582-4934.2012.01579.x
 165. Lee DY, Deng Z, Wang CH, Yang BB (2007) MicroRNA-378 
promotes cell survival, tumor growth, and angiogenesis by tar-
geting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 
104(51):20350–20355. doi:10.1073/pnas.0706901104
